- Home
- OZ vs SLS Comparison
OZ vs SLS Comparison
Compare OZ & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OZ | SLS |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 208.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OZ | SLS |
|---|---|---|
| Price | $50.28 | $3.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 8.9K | ★ 6.3M |
| Earning Date | 03-30-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,217,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 244.98 | N/A |
| 52 Week Low | $49.58 | $0.95 |
| 52 Week High | $82.89 | $5.18 |
Technical Indicators
Market Signals| Indicator | OZ | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 30.92 | 48.45 |
| Support Level | $49.87 | $3.49 |
| Resistance Level | $51.56 | $3.90 |
| Average True Range (ATR) | 0.68 | 0.35 |
| MACD | 0.09 | -0.11 |
| Stochastic Oscillator | 20.71 | 16.88 |
Price Performance
Historical ComparisonAbout OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.